Results 51 to 60 of about 939 (187)

The pharmacotherapeutic management of episodic and chronic migraine with gepants [PDF]

, 2023
The small molecule non-peptide calcitonin gene-related peptide (CGRP) receptor antagonists named gepants offer a breakthrough novel approach in migraine acute and prophylactic drug treatment.
Vécsei László, Anett Csáti, Csáti Anett, János Tajti, Szok Délia, Délia Szok, Tajti János, László Vécsei   +7 more
core   +1 more source

Efficacy, safety and indirect comparisons of lasmiditan, rimegepant, and ubrogepant for the acute treatment of migraine: A systematic review and network meta-analysis of the literature

, 2023
Background: We performed a random-effects network meta-analysis to study the efficacy and safety of newly developed drugs for the acute treatment of migraine attacks. Methods: MEDLINE via PubMed, Embase and The Cochrane Register of Controlled Trials were
Goadsby, Peter J, Huessler, Eva-Maria, Haghdoost, Faraidoon, Lisicki, Marco, Tassorelli, Cristina, Puledda, Francesca, Younis, Samaira, Cristina Tassorelli, Eva-Maria Huessler, Faraidoon Haghdoost, Marco Lisicki, Peter J Goadsby, Francesca Puledda, Samaira Younis   +13 more
core   +1 more source

Ubrogepant and rimegepant: signal detection using spontaneous reports of adverse events from the Food and Drug Administration Adverse Event Reporting System

, 2023
Background: In this study, we fill this gap in knowledge by updating the safety profile of ubrogepant and rimegepant via disproportionality analysis in the Food and Drug Administration (FDA) Adverse Event Reporting System (FAERS), a US-based database ...
Carla Carnovale, Clementi, Emilio, Emilio Clementi, Sessa, Maurizio, Battini, Vera, Vera Battini, Carnovale, Carla, Maurizio Sessa   +7 more
core   +1 more source

Headache: Treatment update

eNeurologicalSci, 2022
Primary headache disorders in particular migraine are one of the most common causes of disability worldwide. Given the high burden of migraine in terms of disability, there has been an effort to develop migraine specific therapies that has led to the ...
Oyindamola I. Ogunlaja, Peter J. Goadsby
doaj   +1 more source

Current status of calcitonin gene-related peptide-based therapies in migraine: a scoping review [PDF]

, 2022
A significant proportion of patients exhibit sub-optimal response to the standard treatment of acute migraine such as triptans and NSAIDs. Even the conventional preventive therapies (e.g.
Ahsan, Marya, Mallick, Ayaz Khurram, Ayaz Khurram Mallick, Marya Ahsan   +3 more
core   +1 more source

Supplemental Material, sj-pdf-1-rep-10.1177_25158163211037344 - Effects of CYP3A4 and P-glycoprotein inhibition or induction on the pharmacokinetics of ubrogepant in healthy adults: Two phase 1, open-label, fixed-sequence, single-center, crossover trials

, 2021
Supplemental Material, sj-pdf-1-rep-10.1177_25158163211037344 for Effects of CYP3A4 and P-glycoprotein inhibition or induction on the pharmacokinetics of ubrogepant in healthy adults: Two phase 1, open-label, fixed-sequence, single-center, crossover ...
Marissa F Dockendorf (11259651), Abhijeet Jakate (8832242), Wendy Ankrom (11259648), Antonia Periclou (8832254), Ramesh Boinpally (8832245), Matthew Butler (387341)   +5 more
core   +1 more source

Network Meta-Analysis of Calcitonin Gene-Related Peptide Receptor Antagonists for the Acute Treatment of Migraine

Frontiers in Pharmacology, 2019
Background: Research has indicated that calcitonin gene-related peptide (CGRP) receptor antagonists can be effective in the acute treatment of migraine. Six major drugs are included within this category: telcagepant, olcegepant, BI 44370, rimegepant (BMS-
Fang Xu, Wenjun Sun
doaj   +1 more source

sj-pdf-1-cep-10.1177_03331024231151419 - Supplemental material for Efficacy, safety and indirect comparisons of lasmiditan, rimegepant, and ubrogepant for the acute treatment of migraine: A systematic review and network meta-analysis of the literature

, 2023
Supplemental material, sj-pdf-1-cep-10.1177_03331024231151419 for Efficacy, safety and indirect comparisons of lasmiditan, rimegepant, and ubrogepant for the acute treatment of migraine: A systematic review and network meta-analysis of the literature by ...
Cristina Tassorelli (665097), Marco Lisicki (14617426), Eva-Maria Huessler (14617393), Francesca Puledda (14617396), Peter J Goadsby (7391171), Faraidoon Haghdoost (14617399), Samaira Younis (8868668)   +6 more
core   +1 more source

New Anti-CGRP Medications in the Treatment of Vestibular Migraine

Frontiers in Neurology, 2022
BackgroundVestibular migraine (VM) is a condition associated with migraine headache, vertigo, dizziness, and balance disturbances. Treatment options are limited.
Justin L. Hoskin, Terry D. Fife
doaj   +1 more source

Doubtful use of placebo following placebo in recent controlled trials of lasmiditan and ubrogepant for the treatment of migraine attacks

, 2022
Purpose: In four large controlled trials with lasmiditan and ubrogepant placebo was administered in the first step to demonstrate an effect on migraine attack.
Tfelt-Hansen, Peer, Jørgensen, Karsten; id_orcid, Diener, Hans Christoph   +2 more
core   +1 more source